Omnix Medical Ltd, based in Israel, has raised $25 million from a Series C funding round to accelerate development of a pipeline of antimicrobials directed against multidrug-resistant infections. Announced on 15 October, the financing was co-led by Harel Insurance & Finance Group, one of Israel’s largest financial institutions, and the European Innovation Council Fund, a venture initiative of the European Commission under the Horizon Europe research programme.
